TR199900732T2 - PDE IV inhibe eden 2-siyanoiminoimidazol türevleri. - Google Patents

PDE IV inhibe eden 2-siyanoiminoimidazol türevleri.

Info

Publication number
TR199900732T2
TR199900732T2 TR1999/00732T TR9900732T TR199900732T2 TR 199900732 T2 TR199900732 T2 TR 199900732T2 TR 1999/00732 T TR1999/00732 T TR 1999/00732T TR 9900732 T TR9900732 T TR 9900732T TR 199900732 T2 TR199900732 T2 TR 199900732T2
Authority
TR
Turkey
Prior art keywords
siyanoiminoimidazole
revleri
eden
pde
inhibits
Prior art date
Application number
TR1999/00732T
Other languages
English (en)
Inventor
Jean Edgard Freyne Eddy
Javier Fernandez-Gadea Francisco
Ignacio Andres-Gil Jos�
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of TR199900732T2 publication Critical patent/TR199900732T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Bu bulus formül (I) 2-siyanoiminoimidazol türevlerine, N-oksit formlarina, farmasötik olarak kabul edilebilir ilave tuzlarina ve stereokimyasal olarak izomerik formlarina iliskindir. Bulus ayni zamanda formül (I) bilesiklerini ve farmasötik bilesimlerini hazirlamak için islemlere iliskindir.
TR1999/00732T 1996-10-02 1997-09-24 PDE IV inhibe eden 2-siyanoiminoimidazol türevleri. TR199900732T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96202749 1996-10-02

Publications (1)

Publication Number Publication Date
TR199900732T2 true TR199900732T2 (tr) 1999-08-23

Family

ID=8224456

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/00732T TR199900732T2 (tr) 1996-10-02 1997-09-24 PDE IV inhibe eden 2-siyanoiminoimidazol türevleri.

Country Status (31)

Country Link
US (1) US6051718A (tr)
EP (1) EP0934280B1 (tr)
JP (1) JP3068208B2 (tr)
KR (1) KR100520002B1 (tr)
CN (1) CN1106387C (tr)
AR (1) AR008875A1 (tr)
AT (1) ATE236884T1 (tr)
AU (1) AU719561B2 (tr)
BG (1) BG64278B1 (tr)
BR (1) BR9712256B1 (tr)
CA (1) CA2267322C (tr)
CY (1) CY2380B1 (tr)
CZ (1) CZ297474B6 (tr)
DE (1) DE69720757T2 (tr)
DK (1) DK0934280T3 (tr)
EE (1) EE03825B1 (tr)
ES (1) ES2196308T3 (tr)
HK (1) HK1020344A1 (tr)
HU (1) HU225158B1 (tr)
IL (2) IL129298A0 (tr)
MY (1) MY116980A (tr)
NO (1) NO312960B1 (tr)
NZ (1) NZ334971A (tr)
PL (1) PL194673B1 (tr)
PT (1) PT934280E (tr)
RU (1) RU2180902C2 (tr)
SI (1) SI0934280T1 (tr)
SK (1) SK285878B6 (tr)
TR (1) TR199900732T2 (tr)
UA (1) UA62939C2 (tr)
WO (1) WO1998014432A1 (tr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200002801T2 (tr) * 1998-04-01 2000-12-21 Janssen Pharmaceutica N.V. PDE IV engelleyici piridin türevleri
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
NZ528820A (en) * 2001-04-19 2007-01-26 Eisai Co Ltd 2-iminopyrrolidine derivatives
JP4510383B2 (ja) 2001-05-23 2010-07-21 田辺三菱製薬株式会社 軟骨疾患修復治療用組成物
CN100358514C (zh) * 2001-07-11 2008-01-02 日研化学株式会社 过敏性眼疾病治疗剂
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
BRPI0117198B1 (pt) 2001-12-14 2018-03-13 Merck Serono S.A. Usos de composição compreendendo um inibidor seletivo de uma isoforma 4 de fosfodiesterase
EP2444393A1 (en) * 2003-02-19 2012-04-25 Eisai R&D Management Co., Ltd. Methods for producing cyclic benzamidine derivatives
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
EP2861580B1 (en) * 2012-06-07 2018-04-25 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
GB2533925A (en) * 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
CN109438434B (zh) * 2018-11-19 2021-05-04 华南农业大学 一种含噁唑环的2-氰基亚氨基噻唑烷类化合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0784461B2 (ja) * 1986-12-19 1995-09-13 日本バイエルアグロケム株式会社 殺虫性ニトロイミノ又はシアノイミノ化合物
JPH05310650A (ja) * 1991-08-22 1993-11-22 Nippon Soda Co Ltd 新規なアミン誘導体、その製造方法及び殺虫剤
MX9304571A (es) * 1992-07-28 1994-05-31 Rhone Poulenc Rorer Ltd Compuestos fanilicos ligados a un arilo o heteroarilo mediante un radical alifatico o un atomo heterogeneo que contiene un grupo eslabonador.
ATE234270T1 (de) * 1992-12-02 2003-03-15 Pfizer Cathecoldiether als selektive pde iv hemmungsmittel
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
EP0711282B1 (en) * 1993-07-28 2002-06-05 Aventis Pharma Limited Compounds as pde iv and tnf inhibitors
EP0714397A1 (en) * 1993-08-19 1996-06-05 Smithkline Beecham Corporation Phenethylamine compounds
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
DE69526790T2 (de) * 1994-06-24 2003-03-06 Euro Celtique Sa Verbindungen zur hemmung von phosphodiesrerase iv
TW424087B (en) * 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives
TW375612B (en) * 1995-04-06 1999-12-01 Janssen Pharmaceutica Nv 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives

Also Published As

Publication number Publication date
DE69720757D1 (de) 2003-05-15
HU225158B1 (en) 2006-07-28
SK34499A3 (en) 2000-04-10
EP0934280A1 (en) 1999-08-11
PT934280E (pt) 2003-08-29
CA2267322C (en) 2007-11-06
EE9900112A (et) 1999-10-15
MY116980A (en) 2004-04-30
HUP9904063A2 (hu) 2000-09-28
PL194673B1 (pl) 2007-06-29
NZ334971A (en) 2000-09-29
CN1232456A (zh) 1999-10-20
NO991560L (no) 1999-06-02
UA62939C2 (uk) 2004-01-15
CZ102899A3 (cs) 1999-07-14
IL129298A0 (en) 2000-02-17
DK0934280T3 (da) 2003-07-21
RU2180902C2 (ru) 2002-03-27
KR20000029964A (ko) 2000-05-25
KR100520002B1 (ko) 2005-10-13
ES2196308T3 (es) 2003-12-16
BG64278B1 (bg) 2004-08-31
EP0934280B1 (en) 2003-04-09
HUP9904063A3 (en) 2000-11-28
BR9712256A (pt) 1999-08-24
IL129298A (en) 2006-04-10
US6051718A (en) 2000-04-18
ATE236884T1 (de) 2003-04-15
PL332573A1 (en) 1999-09-27
WO1998014432A1 (en) 1998-04-09
DE69720757T2 (de) 2004-03-04
JP2000503678A (ja) 2000-03-28
NO312960B1 (no) 2002-07-22
SI0934280T1 (en) 2003-12-31
BG103220A (en) 1999-11-30
CN1106387C (zh) 2003-04-23
AU719561B2 (en) 2000-05-11
CA2267322A1 (en) 1998-04-09
EE03825B1 (et) 2002-08-15
NO991560D0 (no) 1999-03-30
CY2380B1 (en) 2004-06-04
HK1020344A1 (en) 2000-04-14
SK285878B6 (sk) 2007-10-04
CZ297474B6 (cs) 2006-12-13
BR9712256B1 (pt) 2011-04-19
JP3068208B2 (ja) 2000-07-24
AR008875A1 (es) 2000-02-23
AU4779297A (en) 1998-04-24

Similar Documents

Publication Publication Date Title
TR199900732T2 (tr) PDE IV inhibe eden 2-siyanoiminoimidazol türevleri.
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
SE9904505D0 (sv) Novel compounds
HUP0103460A2 (hu) Vírusellenes hatású indolszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
ATE331726T1 (de) Adenine-derivate
ATE301653T1 (de) Pyrazolopyridine
DK0958296T3 (da) Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
DK0951474T3 (da) Nye cyclosporinderivater, deres fremstilling og farmaceutiske præparater deraf
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
YU149791A (sh) Mometason, furoat monohidrat i postupak za njegovo dobijanje
ATE300541T1 (de) Pyrazolopyridinderivate
EE05091B1 (et) Oligosahhariidid, nende valmistamismeetod ja kasutamine ning farmatseutilised kompositsioonid
PA8495101A1 (es) Derivados de 13-metileritromicina
TR199900636T2 (tr) Anti-tümör ajanlari olarak ikameli/katkili heterosaykillar.
ATE233754T1 (de) Diphenyl-piperidin derivate
RS97004A (en) Benzoxazine derivatives as 5-ht6 modulators and uses thereof
NO971625L (no) Nye peptider med immunomodulatoriske effekter
TR199801268T2 (tr) Tasikinin antagonistleri olarak 3-Azetidinilalkilpiperidinler veya pirolidinler.
TR200001452T2 (tr) Bifenilamidin türevleri.
AP9801202A0 (en) Atropisomers of 3-heteroaryl-4(3H)-quinazolinones.
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
TR200002801T2 (tr) PDE IV engelleyici piridin türevleri
ATE274515T1 (de) Pyrazolopyridinderivate